Serum Paraoxonase-1-Related Variables and Lipoprotein Profile in Patients with Lung or Head and Neck Cancer: Effect of Radiotherapy

Figures

• 

  Figure 1. Serum paraoxonase-1 (PON1) concentration, arylesterase (ARE) activity, PON1 specific activity, and receiver operating characteristics (ROC) curves in patients with (A) lung cancer (LC) or (B) head and neck cancer (HNC) before and after radiotherapy (RT). Results are shown as means and standard errors. a p < 0.01, b p < 0.001, with respect to the control group; c p < 0.05, d p < 0.01, e p < 0.001, with respect to pre-radiotherapy, by the Mann-Whitney U-test.

• 

  Figure 2. Number and diameter of the different lipoprotein particles in patients with lung cancer (LC) (A), head and neck cancer (HNC) (B) before and after radiotherapy (RT) and in the control group. Values are log transformed due to the high variability of particle sizes and numbers. Results are shown as means and standard errors. HDL: high-density lipoproteins; IDL: intermediate-density lipoproteins; LDL: low-density lipoproteins; VLDL: very-low-density lipoproteins. The suffix −P indicates number of particles, and the suffix −Z indicates the particle diameter. a p < 0.05, b p < 0.01, c p < 0.001, with respect to the control group by the Mann-Whitney U-test.

• 

  Figure 3. Principal component analysis (PCA) scores, heatmaps, and variable importance in projection (VIP) scores of the partial least squares discriminant analysis (PLSDA) in lung cancer (LC) patients vs. the control group (A) and in LC patients before and after radiotherapy (B). HDL: high-density lipoproteins; IDL: intermediate-density lipoproteins; LDL: low-density lipoproteins; VLDL: very-low-density lipoproteins. The suffix −P indicates number of particles, and the suffix −Z indicates the particle diameter.

• 

  Figure 4. Principal component analysis (PCA) scores, heatmaps, and variable importance in projection (VIP) scores of the partial least squares discriminant analysis (PLSDA) in head and neck cancer (HNC) patients vs. the control group (A) and in HNC patients before and after radiotherapy (B). HDL: high-density lipoproteins; IDL: intermediate-density lipoproteins; LDL: low-density lipoproteins; VLDL: very-low-density lipoproteins. The suffix −P indicates number of particles, and the suffix −Z indicates the particle diameter.

• 

  Figure 5. Relationships between paraoxonase-1-related variables and the toxicity to radiotherapy, clinical status, and response to treatment in patients with lung cancer (A) or head and neck cancer (B). Results are shown as means and standard errors. a p < 0.05, b p < 0.01, by the Mann-Whitney U-test. CR: complete response; DD: distant recurrence of the disease; DFS: disease-free survival; LDPD: loco-regional and distant progression of the disease; LPD: loco-regional progression of the disease; PD: progression of the disease. PON1: paraoxonase-1; PR: partial response; RT: radiotherapy; SD: stabilization of the disease.